
Taking a cutting-edge weight-loss drug could help extremely obese patients drop enough pounds to be eligible for bariatric surgery, a new study shows. Patients with extreme obesity — a BMI of 70 or more — are at higher risk of complications from surgery compared to people who weigh less. Weight loss prior to surgery can lower that risk, but up to now nothing’s been able to help patients lose enough weight to make a difference, researchers say. However, new GLP-1 agonist medications like Ozempic, Wegovy and Zepbound have been shown to help people quickly shed pounds. For this trial, researchers recruited 113 extremely obese patients and assigned them to either a single GLP-1 drug, more than one GLP-1 drug or a medically supervised diet and exercise program. Patients were treated an average of 73 days. People on multiple drugs had the greatest weight loss, dropping about 13% of their total body weight. A single GLP-1 drug helped people lose a little more than 8% of their body weight, while diet and exercise helped participants drop about 6% of their body weight. The findings were presented Thursday at the American Society for Metabolic and Bariatric Surgery’s annual meeting in San Diego. “Combining anti-obesity medications may achieve much greater pre-surgery weight loss than other methods for those with extreme obesity,” said researcher Dr. Phil Schauer, director of… read on > read on >